Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 9:59 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 241–264 of 13,585 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Dermatoses Clear all
Terminated No phase listed Observational

Predicting Response and Toxicity in Patients Receiving Lonafarnib for Breast Cancer

NCT01232881
View directory record Official record
Conditions
Breast Cancer
Interventions
Tumor Sample, Serum Sample
Procedure
Lead sponsor
Hoosier Cancer Research Network
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Apr 28, 2011 · Synced Oct 22, 2026, 9:59 AM EDT
Terminated Phase 2 Interventional

A Trial of a Botanical Drug Containing East Indian Sandalwood Oil (EISO) for the Treatment of Molluscum Contagiosum

NCT02024581
View directory record Official record
Conditions
Molluscum Contagiosum
Interventions
10% East Indian sandalwood oil cream, Placebo Cream
Drug
Lead sponsor
ViroXis Corporation
Industry
Eligibility
2 Years to 17 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Apr 16, 2019 · Synced Oct 22, 2026, 9:59 AM EDT
Completed Phase 3 Interventional Results available

An Investigational Study to Evaluate Experimental Medication BMS-986165 Compared to Placebo and a Currently Available Treatment in Participants With Moderate-to-Severe Plaque Psoriasis

NCT03611751
View directory record Official record
Conditions
Psoriasis
Interventions
BMS-986165, Placebo, Apremilast
Drug · Other
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
1,020 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
89
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tempe, Arizona + 75 more
Source: ClinicalTrials.gov public record
Updated Dec 20, 2022 · Synced Oct 22, 2026, 9:59 AM EDT
Completed No phase listed Observational

Minoxidil Response Testing in Females With Female Pattern Hair Loss

NCT02206802
View directory record Official record
Conditions
Alopecia, Female Pattern Hair Loss
Interventions
5% minoxidil topical foam
Drug
Lead sponsor
Applied Biology, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
2
States / cities
Tucson, Arizona • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 5, 2018 · Synced Oct 22, 2026, 9:59 AM EDT
Completed Phase 3 Interventional Results available

Apremilast as a Direct Treatment for Mild-to-moderate Plaque Psoriasis Versus Placebo: an Analysis of Clinical Safety and Efficacy

NCT03721172
View directory record Official record
Conditions
Psoriasis
Interventions
Apremilast, Placebo
Drug · Other
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
595 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
43
States / cities
Birmingham, Alabama • Fort Smith, Arkansas • Rogers, Arkansas + 38 more
Source: ClinicalTrials.gov public record
Updated May 29, 2024 · Synced Oct 22, 2026, 9:59 AM EDT
Completed No phase listed Observational Results available

Erythropoietic Protoporphyrias: Studies of the Natural History, Genotype-Phenotype Correlations, and Psychosocial Impact

NCT01688895
View directory record Official record
Conditions
Erythropoietic Protoporphyria, EPP, X-Linked Protoporphyria, XLP, XLPP, X-Linked Dominant Erythropoietic Protoporphyria, XLEPP, XLDP
Interventions
Not listed
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
Not listed
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
6
States / cities
Birmingham, Alabama • San Francisco, California • New York, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 17, 2020 · Synced Oct 22, 2026, 9:59 AM EDT
Withdrawn Phase 4 Interventional

Genetically-informed Therapies for Patients With Metastatic Cancer

NCT02000739
View directory record Official record
Conditions
Metastatic Cancer
Interventions
Genetically Informed Therapy
Genetic
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Jul 14, 2014 · Synced Oct 22, 2026, 9:59 AM EDT
Terminated Phase 3 Interventional

Efficacy and Safety Study in the Treatment of Chronic Diabetic Foot Ulcers

NCT00387101
View directory record Official record
Conditions
Diabetic Foot Ulcer
Interventions
Dermal - Living Skin Replacement (Dermal - LSR)
Device
Lead sponsor
ApoPharma
Industry
Eligibility
18 Years to 84 Years
Enrollment
288 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
12
States / cities
Tuscon, Arizona • Mather, California • San Diego, California + 8 more
Source: ClinicalTrials.gov public record
Updated May 2, 2008 · Synced Oct 22, 2026, 9:59 AM EDT
Withdrawn Not applicable Interventional

Feasibility and Effectiveness of a Sleep Hygiene Education Program for Sleep Issues in Breast Cancer Survivors

NCT04232319
View directory record Official record
Conditions
Breast Cancer, Sleep Hygiene
Interventions
Sleep Hygiene Training
Behavioral
Lead sponsor
University of Toledo Health Science Campus
Other
Eligibility
18 Years and older · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Toledo, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 26, 2024 · Synced Oct 22, 2026, 9:59 AM EDT
Not yet recruiting Not applicable Interventional

Use of Silk Fibroin Dressings in Primary Total Hip Arthroplasty

NCT07868900
View directory record Official record
Conditions
Allergic Contact Dermatitis (ACD)
Interventions
Dermabond PRINEO, Silk fibroin
Device
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years and older
Enrollment
350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Oct 22, 2026, 9:59 AM EDT
Completed Phase 2 Interventional

Trial of Active Immunotherapy With Globo H-KLH (OPT-822) in Metastatic Breast Cancer Subjects

NCT01516307
View directory record Official record
Conditions
Metastatic Breast Cancer
Interventions
OPT-822/OPT-821(30 μg/100 μg), Phosphate Buffer Saline (PBS), Cyclophosphamide
Biological · Drug
Lead sponsor
OBI Pharma, Inc
Industry
Eligibility
21 Years and older · Female only
Enrollment
349 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2019
U.S. locations
13
States / cities
Birmingham, Alabama • Fullerton, California • La Jolla, California + 10 more
Source: ClinicalTrials.gov public record
Updated Sep 16, 2020 · Synced Oct 22, 2026, 9:59 AM EDT
Completed Phase 2 Interventional

A Phase 2 Study of PH-10 for the Treatment of Atopic Dermatitis

NCT00690807
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
PH-10
Drug
Lead sponsor
Provectus Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
2
States / cities
Miami, Florida • New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 28, 2009 · Synced Oct 22, 2026, 9:59 AM EDT
Completed Phase 2 Interventional Results available

Preoperative Dose-dense Doxorubicin and Cyclophosphamide Followed by Paclitaxel With Bevacizumab in Operable Breast Cancer

NCT00546156
View directory record Official record
Conditions
Breast Cancer
Interventions
Doxorubicin, Cyclophosphamide, Paclitaxel, Bevacizumab
Drug
Lead sponsor
Ian E. Krop, MD, PhD
Other
Eligibility
18 Years and older
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
4
States / cities
Boston, Massachusetts • Hooksett, New Hampshire
Source: ClinicalTrials.gov public record
Updated May 18, 2021 · Synced Oct 22, 2026, 9:59 AM EDT
Terminated Phase 1 Interventional

A Safety Study of SEA-TGT (SGN-TGT) in Advanced Cancer

NCT04254107
View directory record Official record
Conditions
Non-small Cell Lung Cancer, Gastric Carcinoma, Gastroesophageal Junction Carcinoma, Classical Hodgkin Lymphoma, Diffuse Large B-cell Lymphoma, Peripheral T-cell Lymphoma, Cutaneous Melanoma, Head and Neck Squamous Cell Carcinoma, Bladder Cancer, Ovarian Cancer, Triple Negative Breast Cancer, Cervical Cancer
Interventions
SEA-TGT, sasanlimab, brentuximab vedotin
Drug
Lead sponsor
Seagen Inc.
Industry
Eligibility
18 Years and older
Enrollment
133 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
26
States / cities
Birmingham, Alabama • Tucson, Arizona • Duarte, California + 22 more
Source: ClinicalTrials.gov public record
Updated Feb 10, 2025 · Synced Oct 22, 2026, 9:59 AM EDT
Recruiting Not applicable Interventional

Locally ablatiVe therApy in oLigO-pRogressive sOlid tUmorS (VALOROUS)

NCT06103669
View directory record Official record
Conditions
Breast Cancer, Oligoprogressive, Head and Neck Cancer, Sarcoma, Other Cancer
Interventions
Ablative local therapy
Device
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years and older
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2033
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Jul 8, 2026 · Synced Oct 22, 2026, 9:59 AM EDT
Terminated No phase listed Observational Accepts healthy volunteers

Effect of PARP Inhibitors on Glomerular Filtration Rate

NCT04367467
View directory record Official record
Conditions
Solid Tumor, Ovarian Cancer, Breast Cancer
Interventions
Kidney Function Test
Other
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 26, 2022 · Synced Oct 22, 2026, 9:59 AM EDT
Completed Not applicable Interventional

Treating Cancer-Related Fatigue Through Systematic Light Exposure

NCT01873794
View directory record Official record
Conditions
Hematopoietic Stem Cell Transplantation, Breast Cancer, Fatigue, Mild Cognitive Impairment, Light, Quality of Life, Sleep
Interventions
Bright white light, Dim red light
Device
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
2
States / cities
Hackensack, New Jersey • New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 11, 2017 · Synced Oct 22, 2026, 9:59 AM EDT
Completed Phase 1 Interventional

Pilot Study of Anti-oxidant Supplementation With N-Acetyl Cysteine in Stage 0/I Breast Cancer

NCT01878695
View directory record Official record
Conditions
Stage 0/1 Breast Cancer, Post Biopsy, Pre-surgery
Interventions
IV/oral n-acetylcysteine
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Other
Eligibility
18 Years and older · Female only
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 2, 2025 · Synced Oct 22, 2026, 9:59 AM EDT
Completed Phase 2 Interventional Results available

Neratinib +/- Fulvestrant in Metastatic HER2 Non-amplified But HER2 Mutant Breast Cancer

NCT01670877
View directory record Official record
Conditions
Breast Neoplasms
Interventions
Neratinib, Fulvestrant, Trastuzumab, Tumor biopsy, Research blood sample
Drug · Procedure
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2021
U.S. locations
15
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 11 more
Source: ClinicalTrials.gov public record
Updated Apr 15, 2022 · Synced Oct 22, 2026, 9:59 AM EDT
Completed Phase 1 Interventional

Monoclonal Antibody HuHMFG1 in Treating Women With Locally Advanced or Metastatic Breast Cancer

NCT00096057
View directory record Official record
Conditions
Breast Cancer
Interventions
monoclonal antibody HuHMFG1
Biological
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
3
States / cities
Los Angeles, California • Aurora, Colorado • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 26, 2013 · Synced Oct 22, 2026, 9:59 AM EDT
Completed Phase 2 Interventional Results available

S0800, Nab-Paclitaxel, Doxorubicin, Cyclophosphamide, and Pegfilgrastim With or Without Bevacizumab in Treating Women With Inflammatory or Locally Advanced Breast Cancer

NCT00856492
View directory record Official record
Conditions
Breast Cancer
Interventions
bevacizumab, pegfilgrastim, cyclophosphamide, doxorubicin hydrochloride, paclitaxel albumin-stabilized nanoparticle formulation
Biological · Drug
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years and older · Female only
Enrollment
215 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
365
States / cities
Mobile, Alabama • Little Rock, Arkansas • Berkeley, California + 260 more
Source: ClinicalTrials.gov public record
Updated Jun 27, 2017 · Synced Oct 22, 2026, 9:59 AM EDT
Completed Phase 3 Interventional Results available

A Comparison of 000-0551 Lotion Versus Vehicle Lotion in Subjects With Plaque Psoriasis (Study -304)

NCT01871402
View directory record Official record
Conditions
Plaque Psoriasis
Interventions
000-0551 Lotion, Vehicle Lotion
Drug
Lead sponsor
Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
221 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
10
States / cities
Fremont, California • San Diego, California • Arlington Heights, Illinois + 7 more
Source: ClinicalTrials.gov public record
Updated May 13, 2016 · Synced Oct 22, 2026, 9:59 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Safety and Efficacy of a Topical Scalp Treatment for Dry Scalp Conditions in Children and Adult

NCT03830177
View directory record Official record
Conditions
Dermatitis, Seborrheic, Dry Skin; Eczema
Interventions
Natural Treatment
Drug
Lead sponsor
Ann & Robert H Lurie Children's Hospital of Chicago
Other
Eligibility
1 Year and older
Enrollment
77 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2023
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 24, 2025 · Synced Oct 22, 2026, 9:59 AM EDT
Completed Phase 1Phase 2 Interventional

A Phase I/II Study of BGT226 in Adult Patients With Advanced Solid Malignancies Including Patients With Advanced Breast Cancer

NCT00600275
View directory record Official record
Conditions
Solid Tumors, Breast Cancer, Cowden Syndrome
Interventions
BGT226
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2007
U.S. locations
4
States / cities
Boston, Massachusetts • Las Vegas, Nevada • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Dec 17, 2020 · Synced Oct 22, 2026, 9:59 AM EDT